Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review
| Autor: | Andrew Bullen, Timothy P. Shiraev |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty medicine.drug_class MEDLINE Proton-pump inhibitor Disease 030204 cardiovascular system & hematology Global Health Nitric Oxide 03 medical and health sciences 0302 clinical medicine Cause of Death Medicine Humans 030212 general & internal medicine Myocardial infarction Medical prescription Intensive care medicine business.industry Proton Pump Inhibitors Odds ratio medicine.disease Surgery Survival Rate Clinical equipoise Cardiovascular Diseases Gastroesophageal Reflux Morbidity Cardiology and Cardiovascular Medicine business All cause mortality |
| Zdroj: | Heart, lungcirculation. 27(4) |
| ISSN: | 1444-2892 |
| Popis: | Proton pump inhibitors (PPIs) are a commonly prescribed medication that recent data has linked to an increased risk of cardiovascular morbidity and all cause morbidity. The current study sought to perform a systematic review to investigate the link between PPIs and morbidity and mortality METHODS: A systematic review was carried out as per the PRISMA guidelines, with information databases including Pubmed, Medline, and the Cochrane Review Database. English-language studies of all types published from January 1990 to October 2016 were considered. Dichotomous analysis generating odds ratios was performed using RevMan Version 5.3.Thirty-seven studies were considered, of which five directly compared the effect of PPI use on mortality and/or cardiovascular morbidity (including 22,427 patients in mortality datasets, and 354,446 patients in morbidity datasets). For patients taking PPIs, all cause mortality (OR 1.68 [95% CI 1.53-1.84], p0.001) and rate of major cardiovascular events (OR 1.54 [95% CI 1.11-2.13], p=0.01) were significantly higher.The current systematic review demonstrates that, in patients using PPIs, there was a significant increase in morbidity due to cardiovascular disease. Careful consideration should be given to the prescription of PPIs while clinical equipoise remains. Further research in the area is required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect